The Effect of Empagliflozin on Liver Fat (E-Lift) trial showed that treatment with empagliflozin reduced liver fat [magnetic resonance imaging (MRI)-derived proton density fat fraction (MRI-PDFF)] and alanine transferase (ALT) levels in patients with T2D and NAFLD (14). Here, GPT is linked to type 2 diabetes mellitus.